beclomethasone dipropionate (redirected from Beconase AQ Nasal Spray)

bec·lo·meth·a·sone di·pro·pi·o·nate (bkl-mth-sn d-prp--nt, -zn)

n.

A corticosteroid usually used as an inhalant to treat asthma.

---

beclomethasone dipropionate,

a glucocorticoid.

indications It is prescribed in a metered-dose inhaler in the maintenance treatment of bronchial asthma as prophylactic therapy and as an aerosol for inhalation to treat chronic rhinitis.

contraindications Status asthmaticus, acute asthma, or known hypersensitivity to this drug prohibits its use.

adverse effects Among the more serious adverse reactions of systemic administration are the symptoms of adrenal insufficiency. Hoarseness, sore throat, and fungal infections of the oropharynx and larynx may occur. Good oral and dental hygiene after each use is requisite.

---

beclomethasone dipropionate (bek´lmeth´sōn dī´prō´pēnāt´),

n brand names: oral–Beclovent, Vanceril; nasal–Vancenase AQ Nasal, Beconase AQ Nasal;
drug class: corticosteroid, synthetic;
action: prevents inflammation by depression of migration of polymorphonuclear leukocytes and fibroblasts and reversal of increased capillary permeability;
uses: chronic asthma and rhinitis.

---

beclomethasone dipropionate

a glucocorticoid, commonly used as an inhalant.

---

beclomethasone dipropionate

AeroBec (UK), Asmabec (UK), Beceze (UK), Beclasone (UK), Beclodisk (CA) (UK), Becloforte (CA) (UK), Beclogen (UK), Beconase AQ Nasal Spray, Becotide (UK), Flair (UK), Hayfever Relief (UK), Nasobec (UK), Pollenase Nasal (UK), QVAR

Pharmacologic class: Corticosteroid

Therapeutic class: Anti-inflammatory agent

Pregnancy risk category C

Action

Unclear. May decrease inflammation by stabilizing leukocytic lysosomal membrane, decreasing number and activity of inflammatory cells, inhibiting bronchoconstriction (leading to direct smooth muscle relaxation), and reducing airway hyperresponsiveness.

Availability

Inhalation aerosol: 40-mcg metered inhalation in 7.3-g canister; 80-mcg metered inhalation in 7.3-g canister

Inhalation capsules: 100 mcg, 200 mcg

Nasal spray: 0.042% (25-g bottle containing 180 metered inhalations)

⊘Indications and dosages

➣ Maintenance treatment of asthma as prophylaxis; asthma patients who require systemic steroids for whom adding an inhaled steroid may reduce or eliminate the need for systemic steroids

Adults and children ages 12 and older: When previous therapy was bronchodilator alone, 40 to 80 mcg by oral inhalation (QVAR) b.i.d.; maximum of 320 mcg b.i.d. When previous therapy was inhaled steroid, 40 to 160 mcg by oral inhalation (QVAR) b.i.d.; maximum of 320 mcg b.i.d.

Children ages 5 to 11: When previous therapy was bronchodilator alone, 40 mcg by oral inhalation (QVAR) b.i.d.; maximum of 80 mcg b.i.d. When previous therapy was inhaled steroid, 40 mcg by oral inhalation (QVAR) b.i.d.; maximum of 80 mcg b.i.d.

➣ Seasonal or perennial rhinitis

Adults and children ages 12 and older: One or two inhalations (42 to 84 mcg Beconase AQ Nasal Spray) in each nostril b.i.d.

Children ages 6 to 12: One inhalation (42 mcg Beconase AQ Nasal Spray) in each nostril b.i.d.

Contraindications

• Hypersensitivity to drug
• Status asthmaticus

Precautions

Use cautiously in:
• active untreated infections, diabetes mellitus, glaucoma, underlying immunosuppression
• patients receiving concurrent systemic corticosteroids
• pregnant or breastfeeding patients
• children younger than age 6.

Administration

• Use spacer device to ensure proper delivery of dose and to help prevent candidiasis and hoarseness.
• After inhalation, tell patient to hold his breath for a few seconds before exhaling.
• For greater efficacy, wait 1 minute between inhalations.
• If patient is also receiving a bronchodilator, administer it at least 15 minutes before beclomethasone.
• Discontinue drug after 3 weeks if symptoms don't improve markedly.

Route	Onset	Peak	Duration
Inhalation (nasal)	5-7 days	3 wk	Unknown
Inhalation (oral)	1-4 wk	Unknown	Unknown

Adverse reactions

CNS: headache

EENT: cataracts, nasal irritation or congestion, epistaxis, perforated nasal septum, nasopharyngeal or oropharyngeal fungal infections, hoarseness, throat irritation

GI: esophageal candidiasis

Metabolic: adrenal suppression

Respiratory: cough, wheezing, bronchospasm

Skin: urticaria, angioedema

Other: anosmia, Churg-Strauss syndrome, hypersensitivity reactions

Interactions

None significant

Patient monitoring

• Assess patient's mouth daily for signs of fungal infection.
• Observe patient for proper inhaler use.

Patient teaching

• Instruct patient to hold inhaled drug in airway for several seconds before exhaling and to wait 1 minute between inhalations.
• Advise patient to rinse mouth after using inhaler and to wash and dry inhaler thoroughly to help prevent fungal infections and sore throat.
• Encourage patient to document use of drug and his response in a diary.
• If patient is also using a bronchodilator, teach him to use it at least 15 minutes before beclomethasone.
• As appropriate, review all other significant and life-threatening adverse reactions.